The Patent Finder

Roche Products Limited

Also on record
Records under this name other than patents Roche Products Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Roche Products Limited

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,909,178Dalcetrapib for Therapeutic Use
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
In force
 · High confidence
In forceHigh confidence
US 10,711,303Cetp Inhibitors for Therapeutic Use
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
In force
 · Low confidence
In forceLow confidence
US 11,549,142Cetp Inhibitors for Therapeutic Use
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
In force
 · Low confidence
In forceLow confidence
US 11,389,457Compound and Method for the Prevention of Transmission of Influenza Virus
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
In force
 · High confidence
In forceHigh confidence
US 11,911,394Compound and Method for the Prevention of Transmission of Influenza Virus
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
In force
 · High confidence
In forceHigh confidence
US 12,195,547Dosing for Combination Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibody and ANTI-CD79B Antibody Drug Conjugate
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
In force
 · High confidence
In forceHigh confidence
US 12,729,243Dosing for Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibody
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
In force
 · Medium confidence
In forceMedium confidence
US 6,784,1664'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
conveyed to F Hoffmann la Roche AG - now held by Riboscience LLC
Term ended
Term ended Jun 11, 2022 · High confidence
Term endedTerm ended Jun 11, 2022High confidence
US 8,648,0544'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
conveyed to F Hoffmann la Roche AG - now held by Riboscience LLC
Lapsed on the fee record
Ended Feb 11, 2022 · Low confidence
Lapsed on the fee recordEnded Feb 11, 2022Low confidence
US 6,660,721Anti-Hcv Nucleoside Derivatives
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
Lapsed on the fee record
Ended Dec 9, 2015 · High confidence
Lapsed on the fee recordEnded Dec 9, 2015High confidence
10 of 37 records shown.
Pro members see all 37.
Pro members: see all 37 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited